CWA Asset Management Group LLC Buys 5,275 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

CWA Asset Management Group LLC lifted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report) by 28.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 23,554 shares of the company’s stock after acquiring an additional 5,275 shares during the period. CWA Asset Management Group LLC’s holdings in Harmony Biosciences were worth $782,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Deep Track Capital LP bought a new stake in Harmony Biosciences during the 4th quarter valued at approximately $49,894,000. Vanguard Group Inc. boosted its stake in Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company’s stock valued at $162,883,000 after purchasing an additional 1,262,362 shares during the period. Marshall Wace LLP boosted its stake in Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company’s stock valued at $31,992,000 after purchasing an additional 579,103 shares during the period. Norges Bank bought a new stake in shares of Harmony Biosciences in the 4th quarter worth approximately $16,118,000. Finally, Invesco Ltd. lifted its position in shares of Harmony Biosciences by 173.9% in the 4th quarter. Invesco Ltd. now owns 449,180 shares of the company’s stock worth $15,456,000 after acquiring an additional 285,156 shares during the period. Institutional investors own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HRMY. Mizuho raised their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, May 15th. Needham & Company LLC reiterated a “buy” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, May 6th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Cantor Fitzgerald raised Harmony Biosciences to a “strong-buy” rating in a report on Tuesday, May 13th. Finally, Oppenheimer initiated coverage on Harmony Biosciences in a report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 target price for the company. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Harmony Biosciences has a consensus rating of “Buy” and an average target price of $53.00.

View Our Latest Research Report on Harmony Biosciences

Harmony Biosciences Trading Down 1.8%

HRMY stock opened at $31.89 on Friday. The business has a fifty day moving average price of $32.54 and a 200 day moving average price of $34.00. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 12.17, a P/E/G ratio of 0.48 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.67 and a quick ratio of 3.63.

Harmony Biosciences (NASDAQ:HRMYGet Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to analysts’ expectations of $184.26 million. Harmony Biosciences had a return on equity of 24.32% and a net margin of 20.53%. The business’s revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm posted $0.67 EPS. Analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Profile

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Read More

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report).

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.